Delivery Order SPE2DB24D1205-SPE2DB25FDAQQ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100s, with a ceiling value of $1,718.48 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract that will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 15, 2025. The delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by October 20, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units, with a contract ceiling value of $1,718.48. This firm fixed-price delivery order, with an ultimate completion date of October 1, 2025, represents a non-set-aside competitive award to support federal medical procurement requirements. The award is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $7,733.54 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg on September 22, 2025, with completion scheduled for October 14, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 1 mg tablets in a 30-count package, with a ceiling value of $1,553.40 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of October 6, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed-price contract with a ceiling value of $4,712.76. The contract is scheduled for completion by October 7, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a non-set-aside, competitively awarded procurement and is a child contract issued under...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Envarsus XR 1 mg tablets (30-count units) with a ceiling value of $2,723.16. The contract is structured as a firm fixed-price delivery order with a completion date of October 14, 2025, and represents a non-competed award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages) with a contract ceiling value of $1,711.95. This firm fixed-price delivery order, which has an ultimate completion date of October 16, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $1,711.95 and a firm fixed-price structure. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 29, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FDAQQDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units, with a ceiling value of $1,288.86. This is a firm fixed price delivery order with an ultimate completion date of October 9, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Envarsus XR is an immunosuppressive medication used in transplant care, reflecting the company's role in delivering specialized pharmaceutical commodities across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/18/25 |